Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | PPARD | Q03181 | 10/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196788 | 0.84 | PPARD (0.47) | PPARAPPARDPPARGHSD17B3ROCK2 | |
| SCHEMBL13499383 | 0.80 | MAPT (0.54) | PPARAPPARDPPARGHSD17B3SMN1; SMN2 | |
| SCHEMBL27682431 | 0.80 | PPARD (0.48) | PPARAPPARDPPARGHSD17B3 | |
| SCHEMBL26499325 | 0.79 | PPARD (0.46) | PPARAPPARDPPARGHSD17B3ROCK2 | |
| SCHEMBL13499426 | 0.78 | NPC1 (0.35) | ROCK2NPC1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL13499294 | 0.77 | RXFP1 (0.39) | ROCK2NPC1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL13499289 | 0.76 | PPARD (0.46) | PPARAPPARDPPARGHSD17B3ROCK2 | |
| SCHEMBL13499303 | 0.76 | RXFP1 (0.35) | MAOAMAOBRXFP1 | |
| SCHEMBL16196902 | 0.76 | PPARD (0.48) | PPARAPPARDPPARGHSD17B3ROCK2 | |
| SCHEMBL16196818 | 0.75 | PPARD (0.48) | PPARAPPARDPPARGHSD17B3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | PPARA 1276/4885PPARD 697/4885PPARG 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.